The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
Abstract Background The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), demonstrated its effectiveness for lowering serum phosphate levels, with low daily pill burden, in clinical trials of dialysis patients with hyperphosphatemia. This retrospective database analysis evaluated th...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-12-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-020-02188-8 |
| _version_ | 1818620338888507392 |
|---|---|
| author | Rosa Ramos Charles Chazot Anibal Ferreira Attilio Di Benedetto Konstantin Gurevich Astrid Feuersenger Melanie Wolf Hans-Jürgen Arens Sebastian Walpen Stefano Stuard |
| author_facet | Rosa Ramos Charles Chazot Anibal Ferreira Attilio Di Benedetto Konstantin Gurevich Astrid Feuersenger Melanie Wolf Hans-Jürgen Arens Sebastian Walpen Stefano Stuard |
| author_sort | Rosa Ramos |
| collection | DOAJ |
| description | Abstract Background The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), demonstrated its effectiveness for lowering serum phosphate levels, with low daily pill burden, in clinical trials of dialysis patients with hyperphosphatemia. This retrospective database analysis evaluated the real-world effectiveness of SFOH for controlling serum phosphate in European hemodialysis patients. Methods De-identified patient data were extracted from a clinical database (EuCliD®) for adult hemodialysis patients from France, Italy, Portugal, Russia and Spain who were newly prescribed SFOH for up to 1 year as part of routine clinical care. Serum phosphate and pill burden were compared between baseline (3-month period before starting SFOH) and four consecutive quarterly periods of SFOH therapy (Q1−Q4; 12 months) in the overall cohort and three subgroups: PB-naïve patients treated with SFOH monotherapy (mSFOH), and PB-pretreated patients who were either switched to SFOH monotherapy (PB → mSFOH), or received SFOH in addition to another PB (PB + SFOH). Results 1096 hemodialysis patients (mean age: 60.6 years; 65.8% male) were analyzed, including 796, 188 and 53 patients in, respectively, the PB + SFOH, mSFOH, and PB → mSFOH groups. In the overall cohort, serum phosphate decreased significantly from 1.88 mmol/L at baseline to 1.77–1.69 mmol/L during Q1–Q4, and the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased from 41.3% at baseline to 56.2–62.7% during SFOH treatment. Mean PB pill burden decreased from 6.3 pills/day at baseline to 5.0–5.3 pills/day during Q1–Q4. The subgroup analysis found the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased significantly from baseline during SFOH treatment in the PB + SFOH group (from 38.1% up to 60.9% [Q2]) and the mSFOH group (from 49.5% up to 75.2% [Q2]), but there were no significant changes in the PB → mSFOH group. For the PB + SFOH group, serum phosphate reductions were achieved with a similar number of PB pills prescribed at baseline prior to SFOH treatment (6.5 vs 6.2 pills/day at Q4). SFOH daily pill burden was low across all 3 subgroups (2.1–2.8 pills/day). Conclusion In this real-world study of European hemodialysis patients, prescription of SFOH as monotherapy to PB-naïve patients, or in addition to existing PB therapy, was associated with significant improvements in serum phosphate control and a low daily pill burden. |
| first_indexed | 2024-12-16T17:51:48Z |
| format | Article |
| id | doaj.art-1ad472bf98674f95a0199c5a754f5eeb |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-16T17:51:48Z |
| publishDate | 2020-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-1ad472bf98674f95a0199c5a754f5eeb2022-12-21T22:22:17ZengBMCBMC Nephrology1471-23692020-12-0121111210.1186/s12882-020-02188-8The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysisRosa Ramos0Charles Chazot1Anibal Ferreira2Attilio Di Benedetto3Konstantin Gurevich4Astrid Feuersenger5Melanie Wolf6Hans-Jürgen Arens7Sebastian Walpen8Stefano Stuard9NephroCare Spain, NephrologyNephroCare FranceNephroCare Vila Franca de Xira, NephrologyNephroCare Italy, Medical DirectionFresenius Medical Care RussiaFresenius Medical Care Deutschland GmbHFresenius Medical Care Deutschland GmbHFresenius Medical Care Deutschland GmbHVifor Fresenius Medical Care Renal Pharma, NephrologyFresenius Medical Care, Clinical & Therapeutical GovernanceAbstract Background The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), demonstrated its effectiveness for lowering serum phosphate levels, with low daily pill burden, in clinical trials of dialysis patients with hyperphosphatemia. This retrospective database analysis evaluated the real-world effectiveness of SFOH for controlling serum phosphate in European hemodialysis patients. Methods De-identified patient data were extracted from a clinical database (EuCliD®) for adult hemodialysis patients from France, Italy, Portugal, Russia and Spain who were newly prescribed SFOH for up to 1 year as part of routine clinical care. Serum phosphate and pill burden were compared between baseline (3-month period before starting SFOH) and four consecutive quarterly periods of SFOH therapy (Q1−Q4; 12 months) in the overall cohort and three subgroups: PB-naïve patients treated with SFOH monotherapy (mSFOH), and PB-pretreated patients who were either switched to SFOH monotherapy (PB → mSFOH), or received SFOH in addition to another PB (PB + SFOH). Results 1096 hemodialysis patients (mean age: 60.6 years; 65.8% male) were analyzed, including 796, 188 and 53 patients in, respectively, the PB + SFOH, mSFOH, and PB → mSFOH groups. In the overall cohort, serum phosphate decreased significantly from 1.88 mmol/L at baseline to 1.77–1.69 mmol/L during Q1–Q4, and the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased from 41.3% at baseline to 56.2–62.7% during SFOH treatment. Mean PB pill burden decreased from 6.3 pills/day at baseline to 5.0–5.3 pills/day during Q1–Q4. The subgroup analysis found the proportion of patients achieving serum phosphate ≤1.78 mmol/L increased significantly from baseline during SFOH treatment in the PB + SFOH group (from 38.1% up to 60.9% [Q2]) and the mSFOH group (from 49.5% up to 75.2% [Q2]), but there were no significant changes in the PB → mSFOH group. For the PB + SFOH group, serum phosphate reductions were achieved with a similar number of PB pills prescribed at baseline prior to SFOH treatment (6.5 vs 6.2 pills/day at Q4). SFOH daily pill burden was low across all 3 subgroups (2.1–2.8 pills/day). Conclusion In this real-world study of European hemodialysis patients, prescription of SFOH as monotherapy to PB-naïve patients, or in addition to existing PB therapy, was associated with significant improvements in serum phosphate control and a low daily pill burden.https://doi.org/10.1186/s12882-020-02188-8Chronic kidney diseaseEnd-stage renal diseaseHemodialysisHyperphosphatemiaPhosphate binderSucroferric oxyhydroxide |
| spellingShingle | Rosa Ramos Charles Chazot Anibal Ferreira Attilio Di Benedetto Konstantin Gurevich Astrid Feuersenger Melanie Wolf Hans-Jürgen Arens Sebastian Walpen Stefano Stuard The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis BMC Nephrology Chronic kidney disease End-stage renal disease Hemodialysis Hyperphosphatemia Phosphate binder Sucroferric oxyhydroxide |
| title | The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis |
| title_full | The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis |
| title_fullStr | The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis |
| title_full_unstemmed | The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis |
| title_short | The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis |
| title_sort | real world effectiveness of sucroferric oxyhydroxide in european hemodialysis patients a 1 year retrospective database analysis |
| topic | Chronic kidney disease End-stage renal disease Hemodialysis Hyperphosphatemia Phosphate binder Sucroferric oxyhydroxide |
| url | https://doi.org/10.1186/s12882-020-02188-8 |
| work_keys_str_mv | AT rosaramos therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT charleschazot therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT anibalferreira therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT attiliodibenedetto therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT konstantingurevich therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT astridfeuersenger therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT melaniewolf therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT hansjurgenarens therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT sebastianwalpen therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT stefanostuard therealworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT rosaramos realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT charleschazot realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT anibalferreira realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT attiliodibenedetto realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT konstantingurevich realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT astridfeuersenger realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT melaniewolf realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT hansjurgenarens realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT sebastianwalpen realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis AT stefanostuard realworldeffectivenessofsucroferricoxyhydroxideineuropeanhemodialysispatientsa1yearretrospectivedatabaseanalysis |